Levothyroxine Does Not Cause Thyroid Nodules
Levothyroxine does not cause the development of thyroid nodules—this is a fundamental misunderstanding of thyroid physiology. In fact, the FDA explicitly states that levothyroxine is not indicated for suppression of benign thyroid nodules in iodine-sufficient patients because there are no clinical benefits, and the drug label contains no warnings about nodule formation as an adverse effect 1.
What Levothyroxine Actually Does to Existing Nodules
Suppressive Therapy Effects (Not Causation)
Levothyroxine has historically been used in suppressive therapy to attempt to shrink existing benign thyroid nodules by lowering TSH levels, not to cause them 2, 3, 4.
The 2016 AACE/ACE guidelines explicitly state that levothyroxine suppressive therapy is not recommended in euthyroid patients with benign thyroid nodules because most patients do not require any treatment 5.
The FDA label clearly states levothyroxine is not indicated for suppression of benign thyroid nodules in iodine-sufficient patients, and overtreatment may induce iatrogenic hyperthyroidism rather than nodule formation 1.
Evidence on Nodule Growth Patterns
A 2015 study of 297 patients undergoing thyroid surgery found that therapy with levothyroxine and/or iodine was significantly inversely correlated with nodule growth (odds ratio 0.27), meaning levothyroxine was associated with less growth, not more 6.
The same study demonstrated that rapid thyroid nodule growth occurred only in benign nodules and was not a marker for well-differentiated thyroid cancer, with no rapid growth pattern observed in any case of thyroid malignancy 6.
The Actual Indication: TSH Suppression in Thyroid Cancer
Levothyroxine is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer, where intentional TSH suppression is therapeutic 1.
The 2025 ATA guidelines for differentiated thyroid cancer management confirm that TSH suppression therapy using levothyroxine is part of initial management for thyroid cancer, not a cause of nodular disease 7.
Some patients with thyroid nodules require TSH suppression as part of their treatment plan, and the target TSH level should be reviewed by the treating endocrinologist 8.
Risks of Overtreatment (Not Nodule Formation)
The actual risk of excessive levothyroxine is iatrogenic subclinical hyperthyroidism, which occurs in 14–21% of treated patients and increases the risk of atrial fibrillation (especially in patients >60 years) and accelerated bone loss in postmenopausal women 9.
When levothyroxine is prescribed for hypothyroidism in the absence of thyroid nodules or thyroid cancer, dosing should maintain TSH within the normal reference range (approximately 0.45–4.12 mIU/L) to avoid cardiovascular and skeletal complications 8, 9.
Common Pitfall to Avoid
Do not confuse the presence of thyroid nodules in patients taking levothyroxine with causation. Thyroid nodules are extremely common in the general population—the 2023 European Thyroid Association guidelines note that with widespread use of sensitive imaging, a conspicuous number of thyroid nodules emerge that are mostly benign, asymptomatic, and do not warrant treatment 10. The coexistence of nodules and levothyroxine therapy reflects the high baseline prevalence of both conditions, not a causal relationship.